Ask Warren

DAE HWA Pharm

067080 · KOSDAQ · ₩067080 · 대화제약

₩9,630▲ ₩70 (0.73%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −43.22%
Market cap
₩179B
Enterprise value
₩279B
P/E
40.4×
P/B
2.2×
Dividend yield
0.0%
ROE
5.5%
Net margin
3.0%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−61.3% from the high

₩7,460Today: ₩9,510 – ₩9,800₩24,900

Returns

  • 1W−6.6%
  • 1M−16.9%
  • 3M+22.4%
  • 6M−35.6%
  • YTD−44.8%
  • 1Y−43.2%
Volume today
32,324
0.2× the 20-day average
Traded today
₩312M
Listed shares
18,616,650
EPS (12 months)
₩238
Earnings yield 2.5%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

25Quiet
  • BuzzQuietBuzz 25 of 100 (50 is a normal day for this stock).
  • MomentumWeak-15.9% over the last month; the price is below its 20-day average.
  • News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

DAE HWA Pharm stock overview

DAE HWA Pharm (대화제약, KRX: 067080) is listed on KOSDAQ, in the Biotech & Pharma sector. The company, a South Korean pharmaceutical maker, operates GMP-certified plants producing oral solid drugs, transdermal patches, and anticancer drugs, and through its subsidiary Redox Bio manufactures hyaluronic acid and chemical products. Its shares closed at ₩9,630 on Oct 28, 2026, up 0.73% on the day, giving it a market value of ₩179B.

Key facts

Market cap
₩179B
Sector
Biotech & Pharma
Latest price change
+0.73%
As of
Oct 28, 2026
Main business
The company, a South Korean pharmaceutical maker, operates GMP-certified plants producing oral solid drugs, transdermal patches, and anticancer drugs, and through its subsidiary Redox Bio manufactures hyaluronic acid and chemical products.

Quick answers about DAE HWA Pharm

What does DAE HWA Pharm do?
The company, a South Korean pharmaceutical maker, operates GMP-certified plants producing oral solid drugs, transdermal patches, and anticancer drugs, and through its subsidiary Redox Bio manufactures hyaluronic acid and chemical products. Its business spans pharmaceutical manufacturing and wholesale, medical information systems, pharmaceutical ingredients, and cosmetics and medical devices. Its main products include the anti-infective Cefamethyl tablets, the digestive treatment Furospan tablets, OEM patch products for other drugmakers, and the Amalian filler, with domestic sales through wholesalers and hospitals and overseas sales through local drug companies and distributors, including in Germany, China, and other markets.
What is the market cap of DAE HWA Pharm?
The market capitalisation of DAE HWA Pharm was ₩179B at the close on Oct 28, 2026.
Who are the largest shareholders of DAE HWA Pharm?
According to the latest official filings, the largest reported holders are Ko Jun-jin (28.42%, as of Aug 20, 2026); Kim Su-ji (9.08%, as of Oct 1, 2025); Kim Woon-jang (3.29%, as of Oct 16, 2026).
When is the next earnings report from DAE HWA Pharm?
Korean companies rarely announce results dates in advance. Based on when DAE HWA Pharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own DAE HWA Pharm?
Yes. The National Pension Service held 0.08% of DAE HWA Pharm shares as of Dec 31, 2021.

Company profile

The company, a South Korean pharmaceutical maker, operates GMP-certified plants producing oral solid drugs, transdermal patches, and anticancer drugs, and through its subsidiary Redox Bio manufactures hyaluronic acid and chemical products. Its business spans pharmaceutical manufacturing and wholesale, medical information systems, pharmaceutical ingredients, and cosmetics and medical devices. Its main products include the anti-infective Cefamethyl tablets, the digestive treatment Furospan tablets, OEM patch products for other drugmakers, and the Amalian filler, with domestic sales through wholesalers and hospitals and overseas sales through local drug companies and distributors, including in Germany, China, and other markets.

Written by AI from the company's latest annual report.

Korean name
대화제약
Sector
Biotech & Pharma
Themes
Pharmaceuticals
CEO
김은석(단독대표)
Founded
Jan 1989
Listed
Feb 2003
Listed shares
18,616,650
Fiscal year ends
Month 12
Website
www.dhpharm.co.kr

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: DAE HWA Pharm / 대화제약 / 067080 / KRX:067080

Source: KRX statistical information